SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
___________________
FORM 8-K/A
AMENDMENT 1
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): January 28, 2000
Cistron Biotechnology, Inc.
---------------------------
(Exact name of registrant as specified in charter)
Delaware 0-15271 22-2487972
(State or other jurisdiction (Commission File (IRS Employer
of incorporation) Number) Identification No.)
10 Bloomfield Avenue, Pine Brook, New Jersey 07058
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (973) 575-1700
Not Applicable
(Former name or former address, if changed since last report)
<PAGE> 2
Item 4. Changes in Registrant's Certifying Accountant.
----------------------------------------------
On January 28, 2000, Cistron Biotechnology, Inc. (the
"Company") dismissed the firm of Deloitte & Touche, LLP ("Deloitte") as
certifying accountants. In their place, the Company has engaged the firm of
Wiss and Company to act as certifying accountants for the fiscal year ended
June 30, 2000. The Company's Board of Directors unanimously approved the
dismissal of Deloitte & Touche, LLP and the engagement of Wiss and Company.
For the prior two fiscal years, the opinions of Deloitte
have been unqualified with respect to uncertainty, audit scope and accounting
principle. Further, during those two prior fiscal years and the interim
period of the current fiscal year through January 28, 2000, there have been
no:
(a) disagreements with Deloitte on any matter of accounting
principle or practice, financial statement disclosure, audit scope or audit
procedure which disagreements, if not resolved to the satisfaction of
Deloitte, would have caused it to make reference to the subject matter of
the disagreements in connection with its report, or
(b) reportable events as described in Items 304(a)(1)(iv) and
(v) of Regulation S-K.
Deloitte has been provided with a copy of the foregoing
statements in respect to Item 304(a) and its letter of response has been
attached hereto as an exhibit.
Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.
-------------------------------------------------------------------
(c) Exhibits. The following exhibits are filed herewith:
---------
No. DESCRIPTION
--- -----------
16.1 Letter from Deloitte & Touche dated February 3,
2000
16.2 Letter from Deloitte and Touche dated
February 11, 2000
<PAGE> 3
SIGNATURES
----------
Pursuant to the requirements of the Securities Exchange Act of
1934, as amended, the Registrant has duly caused this report to be
signed on its behalf by the undersigned hereunto duly authorized.
Cistron Biotechnology, Inc.
(Registrant)
By: /s/ISIDORE S. EDELMAN
---------------------
Isidore S. Edelman
Chairman & CEO
Dated: February 11, 2000
<PAGE> 4
EXHIBIT INDEX
-------------
Exhibit Number Description
- --------------- -----------
16.1 Letter from Deloitte & Touche dated February 3, 2000.
16.2 Letter from Deloitte and Touche dated February 11, 2000.
</TEXT/>
</DOCUMENT/>
Deloitte & Touche LLP
Two Hilton Court
PO Box 319
Parsippany, New Jersey 07054-0319
Telephone: (973) 683-7000
Facsimile: (973) 683-7459
February 3, 2000
Isidore S. Edelman, M.D.
Chairman & Chief Executive Officer
Cistron Biotechnology Inc.
P.O. Box 2004
10 Bloomfield avenue
Pine Brook, NJ 07058
Dear Dr. Edelman:
This is to confirm that the client-auditor relationship between Cistron
Biotechnology, Inc. (Comission file No. 0-15271) and Deloitte & Touche LLP
has ceased.
Yours truly,
/s/Deloitte & Touche LLP
- ------------------------
Deloitte & Touche LLP
Cc: Office of the Chief Accountant
SECOS Letter File
Securities and Exchange Commission
Mail Stop 9-5
450 5th Street, N.W.
Washington, D.C. 20549
</TEXT/>
</DOCUMENT/>
Deloitte & Touche LLP
Two Hilton Court
PO Box 319
Parsippany, New Jersey 07054-0319
Telephone: (973) 683-7000
Facsimile: (973) 683-7459
February 11, 2000
Securities and Exchange Commission
Mail Stop 9-5
450 5th Street, N.W.
Washington, D.C. 20549
Dear Sirs/Madams:
We have read and agree with the comments in Item 4 of Form 8-K/A of Cistron
Biotechnology, Inc. dated February 11, 2000.
Yours truly,
/s/Deloitte & Touche LLP
- ------------------------
Deloitte & Touche LLP
